Moderna Schedules Key Financial Review as It Moves Past Covid Vaccines

Cambridge, Thursday, 9 July 2026.
Reporting Q2 earnings on July 31, 2026, Moderna aims to prove its viability beyond COVID-19, fueled by a massive year-to-date stock rally and an upcoming FDA vaccine decision.